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A: CLINICAL STUDY OF A SPASMOLTYIC AGENT
(CYCLOSPASMOL) IN THE TREATMENT OF ELDERLY
ARTERIOSCLEROTIC PATIENTS
By P. J. WARD, L.R.C.P.I., L.M., L.R.C.S.I., D.P.H.
Bessbrook, Newry, Co. Down
THE progressive arterial deterioration which accompanies ageing, may manifest
itself in a variety of symptoms-all causing distress to the patient and increased
problems for the physician. Elderly patients with advanced arteriosclerosis usually
present one or more predominant signs or symptoms against a background of less
obvious mental and physical impairment. Whilst treating a variety of peripheral
vascular disorders in the elderly, with the spasmolytic vascodilator, Cyclospasmol,
one observed that in addition to its control of the presenting complaint, there was
frequently a remarkable improvement in the patient's general mental and physical
well-being. Similar observations have been reported by a number of workers,
including Ravina 1960, 1964; van der Drift 1961; and Hornstein 1961. A more
detailed investigation of Cyclospasmol was made to see if these clinical impressions
could be substantiated.
"Cyclospasmol is the mandelic ester of 3-5-5 trimethylcyclohexanol, and is a
spasmolytic agent acting directly upon the smooth muscle of the vascular wall in
a mode similar to that of papaverine, but with 5 times the activity" (Funcke 1951;
Bijisma et al. 1956). The direct mechanism avoids autonomic effects or interference
with circulating adrenaline. The drug has an extremely low toxicity. The approved
generic name is cyclandelate.
METHOD
The effect of Cyclospasmol was studied in 27 patients aged from 52 and 82
(mean age 71.8 years), who showed some degree of senility, reflected in physical
and mental symptoms. Each suffered several of the manifestations of vascular
insufficiency, apart from peripheral complaints such as Raynaud's disease, inter-
mittent claudication and leg ulcers. The vast majority of these patients also showed
signs of cerebral vascular impairment. This wide variety of symptoms was also
associated with a number of other severe concomitant lesions, some connected
with vascular insufficiency and some not. These included 5 cases of coronary
thrombosis, 3 cases of cerebral haemorrhage, and 2 cases of peptic ulceration.
These conditions were all presented against a background of general senility.
At the commencement of this trial, the subjects were divided into two groups,
the first group receiving Cyclospasmol and the second a placebo. The conditions
of four patients in the control group deteriorated to such an extent that they were
transferred to active treatment after one month. The three groups existing at the
completion of the trial are shown' in table I.
TABLE I
Cyclospasmol Identical placebo Changed to Cyclospasmot
throughout throughout after I month
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zThe duration of therapy was three months in each case. The patients received
an initial dosage of 800 mg. daily for four weeks, followed by a reduction to
400 mg. daily for the remainder of the course. In some cases the higher dosage
was reverted to if considered necessary. Treatment for concomitant disease was
continued, and this included sedatives, soporifics, diabetic regimen, topical appli-
cations and specific dietary instructions. The subjects were examined at the
commencement of the trial and at two weekly intervals until completion.
RESULTS
Taking the series as a whole, a number of significant points arise. In almost
every patient some degree of hypertension was evident, and even on the highest
dosage of Cyclospasmol (800 mg. daily) this was not significantly altered. In the
series not one patient complained of adverse side effects and tolerance to the drug
was excellent.
In the pro-forma clinical information sheet used for each patient, a number of
specific headings were used to describe cerebral function as applied to thought
processes and a number of headings to describe vestibular function. These are
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LEGEND OF TABLE II
Two patients of the control group were treated with Cyclospasmol following completion of
the trial; Patient No. 5-male, aged 74 with coronary thrombosis, anginal pain, hypertension
and intermittent claudication. Poor response on placebo but changed to Cyclospasmol and
showed encouraging improvement. Patient No. 22-male, aged 70 with severe intermittent
claudication also showed no improvement on placebo, but changed to Cyclospasmol with
good results.
131shown in the, main result table (Table II), grouped under the following appropriate
headings: memory loss, confusion/disorientation and Meniere/vertigo/tinnitus.
Graphs Nos. 1 and 2 represent the resultant improvement for each of these
headings for the Cyclospasmol and placebo groups respectively. 83 per cent. of
symptoms of cerebral origin were relieved.
All 16 patients with vertigo alone, or associated with Meniere's disease, showed
a marked improvement on Cyclospasmol-whilst only 2 out of 5 receiving placebo
improved.
When considering the peripheral vascular symptoms, out of 15 patients with
intermittent claudication, 13 receiving Cyclospasmol improved-compared with
only 1 out of 4 in the control group. Whilst on the active treatment 16 out of 18
patients presenting Raynaud's phenomenon, or simple cold hands and feet showed
improvement in their condition, only 2 out of 7 patients in the control group
responded likewise. Graphs 3 and 4 depict progress in this group.
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In the trial, 9 out of 27 patients had severe anginal pain as one predominant
symptom. Two showed a striking improvement with complete cessation of pain,
and 4 recorded improvement which oDuld be classified as good: 1 showed only
slight improvement, all receiving Cyclospasmol treatment. Two patients with severe
anginal pain who were in the control group showed no improvement, and indeed
the severity and incidence of attacks actually increased. It is a remarkable fact
that of the 7 patients in the treated group, none showed improvement of any kind
for at least a month-whilst the average time taken for reduction in pain to be
132demonstrated was 6 weeks. Graphs No. 5 and 6, illustrate the response of the
active and placebo groups respectively.
Of 15 patients who were depressed at the commencement, 13 responded well.
Out of 27 patients included in this trial, 10 needed whole or partial assistance
with dressing and eating; 4 patients receiving Cyclospasmol showed improvement
in this respect. It was also noticeable that the majority of patients receiving
Cyclospasmol were much less restless, both day and night, than those in the
control group.
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Two cases are of particular interest:
A 66 year old woman complained of anginal pain and cramps. Diabetes, coronary
ischaemia and left bundle branch heart block were all present. Her B.P. was 165/85
with moderate arteriosclerosis. The peripheral and cerebral circulation were also
impaired, with a large varicose ulcer, intermittent claudication, cold hands and feet,
paraesthesia, and severe headache and vertigo. Treatment commenced with 800 mg.
Cyclospasmol daily, reduced to 400 mg. after 1 month. At the end of 3 months, these
latter symptoms had practically disappeared. Her hands and feet were only slightly
cold, paraesthesia had gone, and the trophic ulcer was clearer. Intermittent claudication,
restless legs, and the severe cramps had disappeared, and her cerebral signs of headache
and vertigo had also gone; her blood pressure remained constant.
An 82 year old man presented with vertigo and severe leg pain on walking. He was
well nourished, with moderate arteriosclerosis, causing a number of cerebral and
peripheral symptoms. He was slightly confused, memory loss was severe, and vertigo,
intermittent claudication, cold hands and feet, paraesthesia and restless legs were also
present. Improvement was slow in onset, but with Cyclospasmol his general condition
gradually improved. Memory impairment for recent events decreased, enabling him to
be much more useful domestically. His general restlessness was far less, and he slept
better than for many years. He could once more dress, and eat, without assistance.
Pain might still awaken him, but it soon disappeared on movement. His intermittent
claudication was reduced from severe to slight, and he was delighted at being able
to walk much further. Cold hands and feet, paraesthesia and cramp was better, in all
a marked improvement in his condition.
133DISCUSSION AND CONCLUSION
The general senile background present in these elderly patients is represented
by a variety of minor signs and symptoms, each in itself often of small significance,
but when grouped together, of major importance. Assessment cannot be by
examination of each individual component of the senile background due to
the variety of symptoms possible, and the fact that each patient may have a
different combination.
The arguments for and against vasodilator therapy are many, but the absence
of a simple method giving accurate and reproducible measurements of blood flow
in particular tissues, makes substantiations of the various theories difficult. Without
a simple objective test, the practising clinician must depend upon his impressions
received from a number of semi-objective and subjective observations. Particularly
when treating the elderly, the patient's own response and acceptance of the
therapy is of prime importance. Therefore, the improvement in this aspect due
to therapy must, in practice, be assessed by the general observations of the in-
vestigator and the others involved in the care of the patients.
A drug which is to be employed for long term medication should produce a
minimum of side effects likely to cause distress. A highly significant factor in the
success of the trial was the complete absence of variation in blood pressure, with
its attendant risk of irreversible lesions in the cerebral and coronary arteries. Nor
was any effect on the heart rate noticed. The importance of this aspect in the
treatment of the elderly need not be stressed.
The 27 patients who entered the trial presented a total of 116 symptoms which
were directly related to vascular insufficiency. Each subject suffered from at least
two such symptoms.
When these results obtained in peripheral vascular disorders are studied, they
are found to be very much in line with those reported by previous workers. Of
patients with intermittent claudication 86 per cent. improved their walking distance
on Cyclospasmol, whilst only 25 per cent. showed improvement on placebo.
Similar results were recorded in patients showing Raynaud's phenomenon or
suffering from cold hands and feet. My impressions would therefore tend to confirm
those of Gillhespy (1959), who considered Cyclospasmol to be one of the most
effective drugs in the treatment of serious peripheral vascular lesions.
Of particular interest is the beneficial effect of Cyclospasmol where symptoms
of coronary insufficiency exist. All the patients who entered the trial with anginal
pain, showed marked improvement at the end, but it is significant that improve-
ment did not become apparent until approximately two months' treatment had
been completed. The beneficial effects produced by Cyclospasmol where coronary
insufficiency exists coupled with an absence of tachycardial or blood pressure
variations, makes it the ideal vasodilator for elderly patients with concomitant
coronary lesions.
A significant benefit was obtained in those conditions due to cerebral insufficiency.
Both confusion and memory loss showed marked improvement in those receiving
Cyclospasmol therapy. Where the symptoms of vestibular insufficiency were present,
similar results were obtained. The patient benefits greatly from the alleviation of
these symptoms, which tend to cut him off from his normal activities. The effects
of cerebral insufficiency, confusion, memory loss, and disorientation, seriously
134affect the ability of the patient to care for himself. They may lead to malnutrition,
lack of hygiene, and failure to continue treatments as the patient pays less attention
to himself and his surroundings. A vicious circle can develop.
A large number of patients entered the trial with symptoms of depression-
whether depression can be directly due to cerebral in,sufficiency is questionable.
A more valid explanation would be that the depression reflects the patient's own
reaction to the ageing process and the resulting limitation which it puts on his
activities, both physical and mental. In the majority of depressed patients, the
depression was relieved by Cyclospasmol. It is logical that it is more positive
therapy to remove or relieve the basic cause of the depression, than to administer
potent anti-depressive agents.
A significant number of patients who previously needed assistance both in
dressing and eating, were again able to perform these simple functions, following
Cyclospasmol treatment. Such improvement, coupled with relief of confusion and
depression, improved sleep and less restlessness, gave marked benefits both to the
patients and to those responsible for their welfare.
During the course of this trial, the overall improvement in the treated subjects
was so apparent, that a feeling of envy and jealousy was engendered in those
not included in the investigation. This reflects the overall effectiveness of Cyclo-
spasmol in treating general senile problems.
It is my conclusion that Cyclospasmol, in addition to producing marked improve-
ment in specific vascular disorders, at the same time has a beneficial effect on the
general well-being of the elderly patient. I would echo the remarks of Ravina
(1960) "the physical and mental well-being of the elderly is primarily dependent
upon the integrity of the vascular system".
In assessing the results, significant improvements have been recorded in a large
percentage of patients. Arteriosclerosis is a progressive condition and without
treatment the patient's symptoms would normally worsen. Any patient whose
regression is halted may be considered as having benefited from the treatment
-apart from those showing improvement. Examination of Table II will show
such cases in the active treatment group. In the placebo group the deterioration of
conditions is apparent.
There can be no doubt that some of the improvement observed during the
investigations was due to the increased medical attention which the patients re-
ceived, but this is probably manifested in the various placebo effects noted
but this must not be allowed to detract substantially from the very marked improve-
ment shown by the large majority of the patients.
The marked absence of side-effects, and the long period of time necessary
for the greatest benefit to be derived, demonstrate that Cyclospasmol is a spasmo-
lytic of moderate but sustained activity. Maximum improvement usually becomes
apparent within two months.
It is not the purpose of this investigation to discuss the mode of activity of
Cyclospasmol, but the question may be raised whether the slow progressive action
demonstrated in this trial reflects the promotion of collateral circulation, rather
than the questionable dilation of atheromatous vessels. This might also explain the
complete absence of hypotensive and tachycardial effects, the body having ample
time to compensate for the vasodilation and increased collateral circulation.
135- SUMMARY
The spasmolytic vasodilator, Cyclospasmol, was compared with a placebo in
a group of 27 patients showing the senile changes attendant in arteriosclerosis.
A wide variety of symptoms were present. The dosage employed was Cyclospasmol
800 mg. daily for one month, reducing to 400 mg. daily for the remainder of the
three month period of the trial.
1. There were no adverse side-effects reported; Cyclospasmol caused no
variation in blood pressure.
2. Cyclospasmol produced improvement in 85 per cent. of symptoms
due to vestibular insufficiency.
3. Eighty-three per cent. of peripheral vascular symptoms improved on
Cyclospasmol.
4. Seven cases with anginal pain showed marked improvement after a
maximum of 2 months' treatment with Cyclospasmol.
5. There was a significant improvement in the general mental and physical
well-being of the majority of the patients receiving Cyclospasmol.
6. Cyclospasmol produced a slow but progressive improvement in peri-
pheral, coronary and cerebral circulation. It may be necessary to
continue treatment for a number of weeks before improvement is
noticed.
My thanks are due to Brocades (Great Britain) Ltd., for their generous supply of
Cyclospasmol, without which this trial would not have been possible. I also wish to thank
Mr. R. M. Wall, Ph.C., M.P.S., and Mr. D. C. Wren, M.C.S.P., M.R.S.H., for their co-
operation and assistance in preparing this statistical analysis.
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